Mounjaro (Tirzepatide)

Mounjaro (tirzepatide) is a prescription medicine containing tirzepatide, a dual GIP and GLP-1 receptor agonist. In the UK, Mounjaro is authorised for the treatment of type 2 diabetes and for weight management in eligible adults alongside a reduced-calorie diet and increased physical activity.

Product Information

Product Name	Mounjaro
Active Ingredient	Tirzepatide
Medicine Type	Prescription medicine
Drug Class	GIP and GLP-1 receptor agonist
Primary Uses	Type 2 diabetes and weight management
Route	Subcutaneous injection
Manufacturer	Eli Lilly
UK Regulatory Status	Authorised medicine
Intended Use	Use only as prescribed by a qualified healthcare professional

What Is Mounjaro (Tirzepatide)?

Mounjaro is the brand name for a medicine containing tirzepatide. Tirzepatide works on two hormone pathways, glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1).

These pathways are involved in blood glucose regulation, appetite and food intake. Because tirzepatide acts on both receptors, it is classified as a dual GIP and GLP-1 receptor agonist.

Mounjaro is different from single-pathway GLP-1 medicines because tirzepatide combines GIP and GLP-1 receptor activity in one medicine.

Mounjaro for Weight Management

Mounjaro is authorised in the UK for weight management in adults who meet the relevant eligibility criteria. The treatment is used alongside a reduced-calorie diet and increased physical activity.

The MHRA states that Mounjaro can be used for adults with obesity, or for adults who are overweight and have weight-related health problems. It is not intended as a cosmetic treatment for people who simply want to lose a small amount of weight.

Mounjaro for Type 2 Diabetes

Tirzepatide is also authorised for the treatment of type 2 diabetes. Its GIP and GLP-1 activity affects pathways involved in glucose regulation.

Mounjaro should be used according to its approved prescribing information and under appropriate medical supervision. The FDA prescribing information also identifies Mounjaro as a GIP and GLP-1 receptor agonist indicated to improve glycemic control in people with type 2 diabetes.

How Tirzepatide Works

Tirzepatide activates both GIP and GLP-1 receptors.

GIP Receptor Activity

GIP is a hormone involved in the body’s response to food. Tirzepatide’s activity at the GIP receptor forms one part of its dual mechanism.

GLP-1 Receptor Activity

GLP-1 is involved in glucose regulation, appetite signalling and gastrointestinal processes. Tirzepatide activates the GLP-1 receptor as the second part of its mechanism.

The combined GIP and GLP-1 activity is a defining feature of tirzepatide.

Mounjaro Strengths

UK-authorised Mounjaro presentations include 2.5mg, 5mg, 7.5mg, 10mg, 12.5mg and 15mg strengths. The appropriate strength and treatment schedule should be determined by a prescriber based on the patient’s medical circumstances and the approved product information.

A product listing should not imply that customers should select a strength or change their treatment without professional medical advice.

Safety Information

Mounjaro is a prescription medicine and should be used according to its authorised product information.

The FDA prescribing information includes a boxed warning concerning thyroid C-cell tumours observed in rats. Mounjaro is contraindicated in people with a personal or family history of medullary thyroid carcinoma or in people with Multiple Endocrine Neoplasia syndrome type 2.

The MHRA also strengthened safety information for tirzepatide and other GLP-1 or dual GLP-1/GIP medicines in January 2026 because of the risk of acute pancreatitis, including rare severe cases.

Patients should read the official patient information leaflet and speak with their healthcare professional about individual risks, interactions, contraindications and side effects.

Mounjaro in the UK

Mounjaro is a licensed UK medicine. The MHRA authorised tirzepatide under the Mounjaro brand for weight management in November 2023, expanding its use beyond its diabetes indication.

Current UK government guidance confirms that tirzepatide marketed as Mounjaro is one of the licensed medicines available for both diabetes treatment and weight management in eligible patients.

This distinction is important when creating an online product page. Authorisation applies to the specific medicinal product and its approved uses. A separate product containing tirzepatide should not automatically be described as Mounjaro or as an MHRA-authorised medicine.

Buying Mounjaro Online

Mounjaro is a prescription medicine. Online access should be through a legitimate, appropriately regulated healthcare and pharmacy service.

The MHRA advises the public to use authorised sources for medicines and warns about the risks associated with illegal online weight-loss medicines.

When looking for Mounjaro online, customers should verify that the pharmacy is legitimate and that any prescription process is carried out appropriately.

Why Tirzepatide Has Attracted Attention

Tirzepatide has become an important medicine in metabolic healthcare because it combines GIP and GLP-1 receptor activity.

Its authorised uses include:

• Type 2 diabetes management
• Weight management in eligible adults
• Blood glucose control
• Supporting weight reduction when used within an appropriate treatment programme

These uses are subject to the authorised product information and patient eligibility requirements.

Product Quality

Authenticity is particularly important when purchasing prescription medicines online.

Buy legitimate Mounjaro product should have appropriate manufacturer information, packaging, batch information and product documentation. Customers should avoid products from unverified websites that offer prescription medicines without appropriate checks.

Mounjaro should not be confused with unapproved or compounded tirzepatide products. The regulatory status of a specific product depends on the product itself, its manufacturer and the applicable jurisdiction.

Important Information

Mounjaro (tirzepatide) is a prescription medicine. It should only be used by people for whom it has been appropriately prescribed.

Do not change the strength, frequency or method of administration without medical advice.

This page provides general product information and is not a substitute for the official prescribing information, patient information leaflet or advice from a qualified healthcare professional.

Product Summary

Mounjaro (tirzepatide) is a prescription medicine containing tirzepatide, a dual GIP and GLP-1 receptor agonist.

In the UK, Mounjaro is authorised for type 2 diabetes and for weight management in eligible adults. It is used alongside appropriate diet and physical activity measures and should be supplied and used through legitimate healthcare channels.

Mounjaro (Tirzepatide) UK | Weight Management & Diabetes

Meta Description: Mounjaro (tirzepatide) is a prescription medicine authorised in the UK for type 2 diabetes and weight management in eligible adults.Mounjaro Tirzepatide Secondary Keywords: Mounjaro UK, tirzepatide UK, Mounjaro weight management, tirzepatide weight management, Mounjaro prescription, tirzepatide prescription, Mounjaro diabetes, tirzepatide diabetes, GIP GLP-1 medicine, Mounjaro injection Buy Mounjaro, Tirzepatide, Mounjaro UK, Tirzepatide UK, Mounjaro Weight Management, Tirzepatide Weight Management, Mounjaro Prescription, Tirzepatide Prescription, GIP GLP-1, Diabetes Medicine, Weight Management Medicine